Epizyme Inc. (NASDAQ: EPZM) In 2021: Reward Or Shame To Investors? – Marketing Sentinel
Home  »  Company   »  Epizyme Inc. (NASDAQ: EPZM) In 2021: Reward Or Sha...

Epizyme Inc. (NASDAQ: EPZM) In 2021: Reward Or Shame To Investors?

In the last trading session, 1.19 million shares of the Epizyme Inc. (NASDAQ:EPZM) were traded, and its beta was 1.01. Most recently the company’s share price was $3.59, and it changed around $0.11 or 3.16% from the last close, which brings the market valuation of the company to $389.23M. EPZM currently trades at a discount to its 52-week high of $14.30, offering almost -298.33% off that amount. The share price’s 52-week low was $3.48, which indicates that the current value has risen by an impressive 3.06% since then. We note from Epizyme Inc.’s average daily trading volume that its 10-day average is 1.04 million shares, with the 3-month average coming to 875.67K.

Epizyme Inc. stock received a consensus recommendation rating of a Buy, based on a mean score of 2.10. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 1 recommended EPZM as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Epizyme Inc. is expected to report earnings per share of -$0.49 for the current quarter.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored

Epizyme Inc. (NASDAQ:EPZM) trade information

Instantly EPZM has showed a green trend with a performance of 3.16% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 4.51 on Tuesday, 11/23/21 increased the stock’s daily price by 20.4%. The company’s shares are currently down -66.94% year-to-date, but still down -15.93% over the last five days. On the other hand, Epizyme Inc. (NASDAQ:EPZM) is -19.14% down in the 30-day period. We can see from the shorts that 8.62 million shares have been sold at a short interest cover period of 9.96 day(s).

The consensus price target as assigned by Wall Street analysts is $10.80, which translates to bulls needing to increase their stock price by 66.76% from its current value. Analyst projections state that EPZM is forecast to be at a low of $5.00 and a high of $15.00. In order for the stock price to hit the forecast high, the stock would need to plunge -317.83% from its current level, while the stock would need to crash -39.28% from its current level to reach the projected low.

Epizyme Inc. (EPZM) estimates and forecasts

Moreover, analysts have decided to roll up on their fiscal year 2021 revenue estimates. The rating firms predict that it will gain 10.90% in revenue this quarter, and will report an increase of 44.60% in the next quarter. The year-over-year growth rate is expected to be 265.40%, up from the previous year.

Consensus estimates provided by 6 financial analysts predict the company will bring in an average of $12.18 million in revenue for the current quarter. 6 analysts expect Epizyme Inc. to make $22.97 million in revenue for the quarter ending Dec 2021. Forecasts for the next quarter put sales growth at 174.30%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 7.10%. Epizyme Inc. earnings are expected to increase by -19.10% in 2021, but the outlook is positive 38.00% per year for the next five years.

EPZM Dividends

Epizyme Inc.’s next quarterly earnings report is expected to be released around February 21 and February 25.

Epizyme Inc. (NASDAQ:EPZM)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 0.77% of Epizyme Inc. shares, and 97.85% of them are in the hands of institutional investors. The stock currently has a share float of 98.61%. Epizyme Inc. stock is held by 187 institutions, with Primecap Management Company being the largest institutional investor. By Jun 29, 2021, it held 14.95% of the shares, which is about 15.29 million shares worth $127.04 million.

RP Management, LLC, with 8.96% or 9.17 million shares worth $76.18 million as of Jun 29, 2021, holds the second largest percentage of outstanding shares.

>> 7 Top Picks for the Post-Pandemic Economy <<

Primecap Odyssey Aggressive Growth Fund and Primecap Odyssey Growth Fund were the top two Mutual Funds as of Jul 30, 2021. The former held 9.79 million shares worth $64.88 million, making up 9.57% of all outstanding shares. On the other hand, Primecap Odyssey Growth Fund held roughly 4.73 million shares worth around $31.34 million, which represents about 4.62% of the total shares outstanding.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

173226

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

173226

100% free. stop anytime no spam